Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Rolls Out Four-Year Plan To Boost Biopharmaceutical Industry

This article was originally published in PharmAsia News

Executive Summary

At a recent Shanghai biopharmaceutical industry conference, the municipal government unveiled a four-year plan for developing the industry. The city aims to double the industry's 2008 total economic output to RMB 200 billion ($29.3 billion) by 2012, and become China's biopharmaceutical center of innovative product R&D, production and trade. Focusing on high-end chemical drugs, bioproducts and modernized TCM, Shanghai targets to output one third of the global raw pharmaceutical material for anti-HIV drugs, one fifth of China's vaccines and one third of the country's cephems antibiotics. The government has identified six bioindustry bases in Pudong, Minhang, Xuhui, Fengxian, Jinshan and Qingpu districts, and will attract biopharmaceutical enterprises with preferential measures. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072438

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel